Adopting a Framework for Rapid Real-World Data Analyses in Safety Signal Assessment

被引:0
|
作者
Wang, Lu [1 ]
Golchin, Negar [2 ]
von Klot, Stephanie [3 ]
Salinas, Claudia A. [4 ]
Manlik, Katrin [5 ]
Patadia, Vaishali [6 ]
Miller, Mary K. [7 ]
Asubonteng, Julius [8 ]
McDermott, Rachel [9 ]
Barberio, Julie [10 ]
Gipson, Geoffrey [1 ]
机构
[1] Pharmaceut Co Johnson & Johnson, Janssen Res & Dev LLC, 200 Tournament Dr, Horsham, PA 19044 USA
[2] BMS, New York, NY USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Bayer AG, Berlin, Germany
[6] Amgen Inc, Thousand Oaks, CA USA
[7] Genentech Inc, South San Francisco, CA USA
[8] Regeneron, Tarrytown, NY USA
[9] Shionogi, Osaka, Japan
[10] Sanofi, Cambridge, MA USA
关键词
Real-world data (RWD); Safety signal assessment; Pharmacovigilance; Transcelerate; Minimal protocol; Rapid data analysis;
D O I
10.1007/s43441-024-00694-7
中图分类号
R-058 [];
学科分类号
摘要
The expanding availability of real-world data (RWD) has led to an increase in both the interest and possibilities for using this information in postmarketing safety analyses and signal management. While there is enormous potential value from the safety insights generated through RWD, the analysis preparation, execution, and communication required to reliably deliver the evidence can be time consuming. Since the safety signal assessment process is a regulated and timebound process, any supporting RWD analyses require a rapid turnaround of well-designed and informative results. To address this challenge, a TransCelerate BioPharma working group was formed and developed a framework to help teams responsible for safety signal assessment overcome the challenges of working with RWD rapidly to deliver analyses within regulatory timelines. Here, a previously performed safety assessment was evaluated within the context of the developed framework to illustrate how the framework may be adopted in practice.
引用
收藏
页码:1014 / 1022
页数:9
相关论文
共 50 条
  • [41] Data Science Methods for Real-World Evidence Generation in Real-World Data
    Liu, Fang
    ANNUAL REVIEW OF BIOMEDICAL DATA SCIENCE, 2024, 7 : 201 - 224
  • [42] Strategies to Turn Real-world Data Into Real-world Knowledge
    Hong, Julian C.
    JAMA NETWORK OPEN, 2021, 4 (10)
  • [43] Deriving Real-World Insights From Real-World Data
    Baker, Stuart G.
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (09) : 664 - 665
  • [44] Sequential Epidemiological Analyses of Real-World Data: A Tool for Prospective Drug Safety Surveillance from the Rofecoxib Example
    Abbasi, Saad Hanif
    Lund, Lars Christian
    Hallas, Jesper
    Pottegard, Anton
    DRUG SAFETY, 2025, : 489 - 502
  • [45] Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence
    Richard E. Gliklich
    Michelle B. Leavy
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 303 - 307
  • [46] Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence
    Gliklich, Richard E.
    Leavy, Michelle B.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 303 - 307
  • [47] REAL-WORLD DATA OF ADR REPORTS IN SIGNAL DETECTION - DME PERSPECTIVE
    Marques Rodrigues, N.
    Silva, A.
    VALUE IN HEALTH, 2021, 24 : S176 - S176
  • [48] A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
    Gray, Christen M.
    Grimson, Fiona
    Layton, Deborah
    Pocock, Stuart
    Kim, Joseph
    DRUG SAFETY, 2020, 43 (07) : 623 - 633
  • [49] A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
    Christen M. Gray
    Fiona Grimson
    Deborah Layton
    Stuart Pocock
    Joseph Kim
    Drug Safety, 2020, 43 : 623 - 633
  • [50] Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group
    Han, Hye Sook
    Lee, Kyoung Eun
    Suh, Young Ju
    Jee, Hee-Jung
    Kim, Bum Jun
    Kim, Hyeong Su
    Lee, Keun-Wook
    Ryu, Min-Hee
    Baek, Sun Kyung
    Park, In Hae
    Ahn, Hee Kyung
    Jeong, Jae Ho
    Kim, Min Hwan
    Lee, Dae Hyung
    Kim, Siheon
    Moon, Hyemi
    Son, Serim
    Byun, Ji-Hye
    Kim, Dong Sook
    An, Hyonggin
    Park, Yeon Hee
    Zang, Dae Young
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14